Yahoo Finance 
Stocks in play: BioVaxys Technology Corp.
Announced today that it has filed with the United States Patent & Trademark Office ("USPTO") an intent-to-use application to register the mark CoviDTH®, it's novel disposable T-cell immune response diagnostic for SARS-CoV-2. BioVaxys President and CEO Kenneth Kovan commented "As we get closer to market, we needed to register a trademark that would be descriptive, memorable, and defendable. CoviDTH® is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19." In another action that further builds their IP portfolio, BioVaxys broadened the patent coverage for its bihaptenized tumor antigen vaccine platform by filing an international patent application through the Patent Cooperation Treaty ("PCT") with additional claims for cervical cancer. In addition to cervical and ovarian cancer, patent claims for BioVaxys' cancer vaccine platform align with their oncology vaccine development plans and include other gynecological cancer targets such as uterine, vaginal, vulvar, and endometrial cancers. Other tumor targets of commercial interest covered by its patent applications include melanoma, lung cancer, renal cell carcinoma, pancreatic cancer, colorectal cancer, breast cancer, and leukemia. BioVaxys Technology Corp. shares C.BIOV are trading down 1 cent at $0.29.
Read:
